Kahori Miyamoto
Overview
Explore the profile of Kahori Miyamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
14
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyamoto K, Akita T, Yamashita C
Pharmaceutics
. 2022 Apr;
14(4).
PMID: 35456593
Human lung deposition data is non-mandatory for drug approval but very useful for the development of orally inhaled drug products. Lung deposition of inhaled drugs can be quantified by radionuclide...
2.
Miyamoto K, Yanagisawa M, Taga H, Yamaji H, Akita T, Yamashita C
Pharmaceutics
. 2021 May;
13(5).
PMID: 33946783
It has been previously reported that active vitamin D3 (VD3) is a candidate drug that can repair alveolar damage in chronic obstructive pulmonary disease at a very low dose. We...
3.
Systemic Delivery of hGhrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys
Miyamoto K, Ishibashi Y, Akita T, Yamashita C
Pharmaceutics
. 2021 Feb;
13(2).
PMID: 33562278
Ghrelin is the peptide that increases the hunger sensation and food intake and is expected to be clinically applied for treatment of diseases such as cachexia and anorexia nervosa. In...
4.
Miyamoto K, Taga H, Akita T, Yamashita C
Pharmaceutics
. 2020 Oct;
12(10).
PMID: 33076510
Recently, statistical techniques such as design of experiments are being applied for efficient optimization of oral formulations. To use these statistical techniques for inhalation formulations, efficient methods for rapid determination...
5.
Ohori R, Kiuchi S, Sugiyama S, Miyamoto K, Akita T, Yamashita C
Int J Pharm
. 2020 Mar;
581:119255.
PMID: 32217154
Inhalation of proteins/peptides has recently received attention as various biopharmaceuticals have emerged on the market. Novel lyophilisates for dry powder inhalation (LDPIs), which are aerosolized by air impact, have been...